Dyadic International (DYAI) achieved multiple development milestones in its global health partnerships using its C1 protein production platform, the company said Tuesday.

Researchers completed a production phase from plasmid to purified protein in roughly 15 days under a joint project with international health foundations, the company said.

The company expects to send refined viral samples to Scripps Research for vaccine studies by the end of July, Dyadic International said.

Shares of the company were up 2.9% early Tuesday.

Price: 1.00, Change: +0.03, Percent Change: +2.88